Related Experiment Video
Updated: May 29, 2026

Reprogramming Pancreatic Ductal Adenocarcinoma to Pluripotency
Published on: February 2, 2024
[Postoperative adjuvant treatment for pancreatic cancer: present status and future perspective]
Katsuhiko Uesaka1, Hideyuki Kanemoto, Teiichi Sugiura
1Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center Hospital.
Abstract:
To improve surgical results after resection of pancreatic cancer, clinical trials with postoperative adjuvant treatment have been aggressively performed. In Europe, chemotherapy has been approved as a postoperative adjuvant therapy based on the results of the European Study Group for Pancreatic Cancer-1(ESPAC-1)trial published in 2004, and the Charité Onkologie (CONKO)-001 study published in 2007. In Japan, postoperative chemotherapy has been supported, as in Europe, under the influence of the results from the Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer-02(JSAP-02)trial, published in 2009. In recent years, gemcitabine has been recognized as the first choice for adjuvant chemotherapy after surgery. Clinical trials with gemcitabine, fluorouracil, and molecular targeting agents are now under way.
Related Concept Videos
Chronic Pancreatitis II: Collaborative Care
Assessment:
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Acute Pancreatitis II: Clinical Manifestations and Management
Acute Pancreatitis I: Introduction
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Acute Pancreatitis I: Introduction